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Type 1 autoimmune diabetes is an autoimmune disease characterized by specific
destruction of pancreatic β-cells producing insulin. Recent studies have shown that
gut microbiota and immunity are closely linked to systemic immunity, affecting the
balance between pro-inflammatory and regulatory immune responses. Altered gut
microbiota may be causally related to the development of immune-mediated diseases,
and probiotics have been suggested to have modulatory effects on inflammatory
diseases and immune disorders. We studied whether a probiotic combination that has
immunomodulatory effects on several inflammatory diseases can reduce the incidence
of diabetes in non-obese diabetic (NOD) mice, a classical animal model of human T1D.
When Immune Regulation and Tolerance 5 (IRT5), a probiotic combination comprising
Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus reuteri, Bifidobacterium
bifidium, and Streptococcus thermophiles, was administered 6 times a week for 36
weeks to NOD mice, beginning at 4 weeks of age, the incidence of diabetes was
significantly reduced. Insulitis score was also significantly reduced, and β-cell mass was
conversely increased by IRT5 administration. IRT5 administration significantly reduced
gut permeability in NOD mice. The proportion of total regulatory T cells was not changed
by IRT5 administration; however, the proportion of CCR9+ regulatory T (Treg) cells
expressing gut-homing receptor was significantly increased in pancreatic lymph nodes
(PLNs) and lamina propria of the small intestine (SI-LP). Type 1 T helper (Th1) skewing
was reduced in PLNs by IRT5 administration. IRT5 could be a candidate for an effective
probiotic combination, which can be safely administered to inhibit or prevent type 1
diabetes (T1D).
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INTRODUCTION
Type 1 autoimmune diabetes is a classical organ-specific autoimmune disease resulting
from immune-mediated destruction of pancreatic β-cells producing insulin. While genetic
predisposition plays a critical pathogenic role both in patients with T1D and in animal models of
autoimmune diabetes, environmental factors are also important for the development of clinical
disease.Among environmental factors, the microbiota is emerging as a crucial element that
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can influence T1D by modulating local and systemic host
immunity. Particularly, gut microbiota represents the largest
microbial population in humans or animals which affects not
only immune responses but also other vital processes of life, such
as nutrient uptake.
Currently, microbiota studies are gaining strong popularity
since new methods of microbiota identification, such as 16s
rRNA gene sequencing revolutionized the field. However,
the role of microbiota in T1D has been long recognized
as exemplified by the decade-old “hygiene hypothesis” (1).
According to the hypothesis, recent increases in the incidence
of autoimmune or allergic diseases including T1D could be
due to improved sanitation and relative paucity of exposure to
microorganisms that are necessary for the proper maturation
or functional adaptation of the immune system (2). Microbial
exposure can influence host immunity by multiple mechanisms
including Th1/type 2 T helper (Th2) deviation or regulatory
cell modulation (3). Consistently, when NOD mice, a classical
model of autoimmune diabetes, were rendered germ-free,
insulitis was accelerated which was accompanied by increased
Th1 and Th17 cells in the mesenteric lymph nodes (MLNs)
and PLNs (4); however, the incidence of diabetes was not
significantly changed in germ-free NOD mice (4, 5), showing
complex nature of the development of the disease phenotype
in vivo. Regarding specific microorganisms that can influence
autoimmune diabetes, Lactobacillus johnsonii, Lactobacillus
casei, Bacillus cereus, Akkermansia muciniphila, Segmented
Filamentous Bacteria (SFB), a specific strain of Clostridium
butyricum or probiotic comprising such bacteria have been
reported to reduce the incidence of diabetes in NOD mice or BB
rat, a rat model of autoimmune diabetes by modulating cytokine
profile, Treg cells, Th cell polarization, or barrier function (5–
10). Viruses, such as norovirus or lymphocytic choriomeningitis
virus (LCMV) have also been shown to inhibit the development
of autoimmune diabetes in NODmice (11, 12).
Because of profound effects of microbiota on host immunity
and therapeutic potential, a large array of microbes or their
products has been employed to treat or manage diverse
inflammatory diseases, metabolic diseases and cancers (13–
16). Particularly, probiotics, live microorganisms conferring a
beneficial physiological effect on the host, such as maintenance
of host immune homeostasis, nutrient metabolism or protection
of neonates from infection (17–19), are attractive candidates
as potential therapeutic agents against those diseases. We have
recently reported a probiotic combination comprising 5 bacteria,
IRT5, that has therapeutic effects on several autoimmune or
inflammatory disease models, such as inflammatory bowel
disease, atopic dermatitis, rheumatoid arthritis, and experimental
autoimmune encephalomyelitis (20, 21). Here, we studied
whether the microbial combination could be effective in
autoimmune diabetes of NOD mice.
MATERIALS AND METHODS
Animals
NOD mice and BDC2.5/NOD T cell receptor (TCR)-transgenic
mice purchased from Jackson Laboratory (Bar Harbor, ME, USA)
were maintained in a specific-pathogen-free environment in the
vivarium of Yonsei University College of Medicine. Mice were
considered diabetic if blood glucose levels were >16.7 mmol/l
on a single measurement or > 13.9 mmol/l on consecutive
measurements. The incidence of diabetes in female and male
NOD mice was about 70 and 30%, respectively, at 24 weeks of
age. All animals had free access to water and laboratory chow
and were kept on a 12-h light/dark cycle. All mouse experiments
were conducted in accordance with the Public Health Service
Policy in Humane Care and Use of Laboratory Animals. Mouse
experiments were approved by the IACUC of the Department
of Laboratory Animal Resources of Yonsei University College of
Medicine, an AAALAC-accredited unit.
Probiotic Administration
IRT5 (kindly provided by Korea Yakult Co, Giheung, Korea)
was mixtures of live bacteria consisting of 1 × 109 colony-
forming unit (cfu) of each of the following strains in 100
µl: Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus
reuteri, Bifidobacterium bifidium, and Streptococcus thermophiles.
Four-weeks-old female NOD mice were randomly assigned to
experimental group treated with IRT5 (NOD-IRT5) or control
group treated with PBS (NOD-PBS). Mice were healthy and
non-diabetic before starting IRT5 administration, and no adverse
effect of IRT5 administration was observed. Study design
and general scheme of probiotic administration are shown in
Figure S1.
Insulitis Scoring and β-Cell Mass
Insulitis score was determined using paraffin-embedded H&E
stained sections as previously described (22). In brief, the severity
of insulitis was evaluated from more than 30 pancreatic islets
from 3 or more parallel sections of different cut levels per mouse.
The degree of insulitis was categorized into 4 groups: 0, no
insulitis; 1, periinsulitis with or without minimal lymphocytic
infiltration into islets; 2, invasive insulitis with islet destruction
of ≤ 50%; 3, islet destruction of > 50%. Relative β-cell mass was
measured by point counting after insulin immunohistochemistry
of pancreatic sections, as previously described (23). Insulitis
scoring and β-cell mass determination were conducted after 12
weeks of IRT5 administration.
Insulin Autoantibody (IAA) Measurement
Serum mouse IAA levels were determined using an ELISA kit
(ABclonal, Woburn, MA, USA), according to the manufacturer’s
instructions. Briefly, 50 µl of enzyme solution was added to
samples and standards in 96-well plates. After incubation for 1 h
at 37◦C in a humid chamber and washing, substrate was added
for incubation for 15min at room temperature without light
exposure. After adding 50 µl of stop solution to each well, optical
density (O.D.) was determined at 450 nm.
Gut Permeability
Permeability of gut epithelium was determined as described
(24). In brief, mice fasted for 4 h were orally administrated
with 60 mg/100 g body weight permeability tracer of fluorescein
isothiocyanate (FITC)-labeled dextran (molecular weight, 4,000)
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(Sigma, St. Louis, MO, USA) and peripheral blood was collected
4 h later. Serum samples were diluted in equal volumes
of PBS, and the serum FITC-dextran concentrations were
determined using a fluorescence spectrophotometer (GloMax-
Multi Detection System) (Promega, Madison, WI, USA) at an
excitation wavelength of 490 nm and an emission wavelength of
540 nm.
Immunohistochemistry
For immunohistochemical staining of tight junction proteins, 2–
4µm thin sections of the small intestine (SI) were deparaffinized
and rehydrated. After antigen retrieval by microwaving in Tris-
EDTA buffer (10 mmol/l, pH 9.0) for 10min and blocking
in 10% goat serum for 30min, sections were incubated with
ZO-1 antibody (Ab) (Invitrogen, Carlsbad, CA, USA) for
30min at room temperature. Sections were then incubated
with biotinylated secondary antibody for 30min, followed by
incubation with Vectastain ABC (Vector Lab, CA, USA) and
DAB (Invitrogen) staining. Between each step, sections were
rinsed three times in TBST buffer (137mM NaCl-20mM Tris,
pH 7.4–0.1% Tween 20). After DAB staining, sections were
counterstained with Mayer’s hematoxylin.
T Cell Priming
T cell priming was evaluated by an adoptive transfer system using
carboxyfluorescein succinimidyl ester (CFSE) (Molecular Probes,
Eugene, OR, USA)-labeled lymphocytes as described (25). In
brief, naïve CD4+ T cells were prepared from the pooled spleens
of young BDC2.5/NOD mice by the negative-selection method
using a MACS CD4+ T cell isolation kit (Miltenyl Biotech,
Alburn, CA, USA). The purity of CD4+ T cells was > 95%.
CFSE-labeled CD4+ T cells (2 × 106 cells) were transferred into
recipient mice by tail vein injection. Lymphoid cells in PLNs,
MLNs and SI-LP were harvested 66 h after transfer, and single
cell suspension was analyzed for CFSE dilution by flow cytometry
gated on CD4+ and Vβ4+ cells.
Flow Cytometry
Regulatory T (Treg) cell proportion was determined as published
(16). In brief, single-cell suspensions of lymphocytes were
manually prepared from PLNs, MLNs or SI-LP of mice. To
harvest SI-LP cells, SI was opened and washed in ice-cold PBS.
After washing with PBS, tissues were transferred to a flask
containing 10% FBS-10 mmol/l EDTA in PBS. After vigorous
shaking, tissues were passed through a strainer. Tissues were
then minced in 10ml RPMI 1640 containing 0.5mg collagenase
D (Roche, Indianapolis, IN, USA) and DNase I (Roche). After
stirring for 20min at 37◦C, the supernatant was collected for
a total of 3 times. Cell pellet obtained after centrifugation at
520 g for 5min was washed and resuspended in RPMI-2% FBS.
SI-LP mononuclear cells were purified on a 40–75% Percoll
(GE Healthcare Life Sciences, Uppsala, Sweden) gradient by
centrifugation at 930 g, 25◦C for 20min. Cells were resuspended
in PBS-2% FBS-2mM EDTA. After Fc blocking, PLNs, MLNs
or SI-LP cells were incubated with a mixture of anti-CD3ε
and -CD4 Abs (eBioscience, San Diego, CA, USA) in PBS-2%
FBS-2mM EDTA at 4◦C for 30min. After permeabilization,
cells were incubated with anti-mouse/rat FOXP3 (FJK-16s) Ab
(eBioscience) at 4◦C for 30min. The FoxP3 Staining Buffer Set
(eBioscience) was used for intracellular staining according to the
manufacturer’s instructions.
To evaluate Th or cytotoxic T (Tc) cell skewing, cells
in PLNs, MLNs, and SI-LP were stimulated immediately
after isolation with phorbol 12-myristate 13-acetate (Sigma),
ionomycin (Sigma) in the presence of BD GolgiStop (BD
Biosciences) at 37◦C for 4 h. After Fc blocking, cells were stained
with fluorophore-labeled Abs specific for CD3ε, CD4, or CD8
(eBioscience) in PBS-2% FBS-2mM EDTA at 4◦C for 30min.
After surface staining, cells were stained with anti-interleukin
17A (IL-17A) (eBioscience) and -IFN-γ Ab (eBioscience) at 4◦C
for 30min using the Cytofix/Cytoperm kit (BD Pharmingen, San
Diego, CA, USA), according to the manufacturer’s instructions.
Cells were fixed in 0.5% paraformaldehyde, and then multi-
color flow cytometry was performed using a FACSCalibur
flow cytometer (BD Biosciences, San Jose, CA, USA). Data
were analyzed with FlowJo software (Tree Star, Inc., Ashland,
OR, USA).
RNA Isolation and Quantitative RT-PCR
RNA was prepared from primary tissues or extracted from
paraffin-embedded sections using the Tizol or QIAamp DNA
FFPE Tissue Kit (Qiagen, Valencia, CA, USA). cDNA was
synthesized using Superscript II (Invitrogen) and oligo (dT)12-
18 primers. Real-time RT-PCR was performed using SYBR green
(Takara, Shiga, Japan) in ABI PRISM 7000 (Applied Biosystems,
Foster City, CA, USA). All expression values were normalized to
β-Actin or GapdhmRNA levels.
Primer Sequences for Quantitative RT-PCR
mouse Zo-1-F, 5′-CCCCTCTGTCCAGCTCTTC-3′; mouse
Zo-1-R,5′-CACCGGAGTGATGGTTTTCT-3′; mouse Occludin-
F, 5′-CCTCCAATGGCAAAGTGAAT-3′; mouse Occludin-R,
5′-CTCCCCACCTGTCGTGTAGT-3′; mouse Claudin 1-F,
5′-TGG GTT TCA TCC TGG CTT CT-3′; mouse Claudin






All values are expressed as the means ± SE. The incidence of
diabetes was plotted as the Kaplan-Meier curve and compared
using the logrank test. Two-tailed Student’s t-test was employed
to compare values between two groups. P-values <0.05 were
considered significant.
RESULTS
Reduced Incidence of Diabetes by
Probiotic Combination
Since IRT5, a combination of 5 bacteria (Lactobacillus
acidophilus, Lactobacillus casei, Lactobacillus reuteri,
Bifidobacterium bifidium, and Streptococcus thermophilus)
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FIGURE 1 | Incidence of diabetes in female NOD mice. (A) IRT5 was administered since 4 weeks of age for 36 weeks, and the incidence of diabetes was monitored.
Control group was treated with solvent only in the same manner (n = 10 for NOD-PBS and 24 for NOD-IRT5). (B,C) Changes of pancreatic islets. Insulitis score (B)
and relative β-cell mass (C) were determined after 12 weeks of IRT5 administration as described in the MATERIALS AND METHODS (n = 8 for NOD-PBS and 9 for
NOD-IRT5 in B; n = 7 for NOD-PBS and 8 for NOD-IRT5 in C). (D) Serum level of insulin autoantibody (IAA) was determined in NOD-PBS and NOD-IRT5 using ELISA
(n = 6 for NOD-PBS and 6 for NOD-IRT (**p < 0.01; *p < 0.05).
has been shown to be effective against several autoimmune and
inflammatory disorders (20, 21), we administered 5 × 108 cfu
IRT5 to female NOD mice by oral gavage six times a week for 36
weeks beginning at 4 weeks of age and monitored blood glucose
level. The incidence of diabetes was significantly reduced in NOD
mice treated with IRT5 compared to control NOD mice treated
with PBS (Figure 1A). Consistent with the reduced incidence of
diabetes, insulitis score was also significantly reduced in mice
treated with IRT5 (Figure 1B). Conversely, β-cell mass was
higher in mice treated with IRT5 compared to control NOD
mice (Figure 1C). Serum level of IAA, an index of autoimmunity
in NOD mice (26), was also reduced in NOD mice treated with
IRT5 compared to control mice (Figure 1D).
Reduced Gut Permeability by Probiotic
Combination
To study the mechanism of the reduced incidence of
autoimmune diabetes by IRT5, we studied possible changes
of permeability of gut epithelium since the intestine is the
first organ contacting oral administered probiotics and gut
permeability is changed in patients with T1D or animal
models of autoimmune diabetes, potentially contributing to the
acceleration of islet autoimmunity (27–29). Real-time RT-PCR
showed that the expression of Zo-1 encoding a tight junction
protein that constitutes critical physical barrier of the intestine,
was significantly increased in the SI of NOD mice treated with
IRT5 for 12 weeks (Figure 2A), suggesting improved gut barrier
function. The expression of Occludin encoding another tight
junction protein, was also increased after IRT5 administration
for 12 weeks, while statistical significance was not achieved
(Figure 2A). In contrast, the expression of Claudin-1 that
controls epithelial permeability as a tight junction protein (30)
was not significantly changed after IRT5 treatment (Figure 2A).
Significantly increased expression of ZO-1 after IRT5 treatment
was confirmed by immunohistochemistry (Figure 2B). When we
investigated the intestinal barrier function of gut epithelium by
measuring the amount of circulating FITC-dextran 4 h after oral
gavage with FITC-dextran, a significantly reduced serum content
of FITC-dextran was observed in mice treated with IRT5 for 12
weeks compared to control NOD mice (Figure 2C), supporting
enhanced barrier function by IRT5.
Increased Gut-Homing Treg Cells by
Probiotic Combination
We next studied changes of immune parameters involved in
β-cell autoimmunity after administration of IRT5. We first
assessed priming of diabetogenic T cells using the BDC2.5 TCR
transgenic system that occurs in PLNs and is critical in the
sensitization of diabetogenic T cells in vivo (29). The transgene-
encoded TCR, derived from a diabetogenic BDC2.5 T cell clone,
recognizes chromogranin A as a β-cell autoantigen in the context
of MHC class II molecule I-Ag7 (31). We observed no significant
change of the proliferation of transferred BDC2.5 T cell in
NOD mice treated with IRT5 (Figure S2), indicating that IRT5
administration does not influence diabetogenic T cell priming
in PLNs.
To assess other immune parameters modulating β-cell
autoimmunity, we studied Treg cells that are induced by
IRT5 and can exert inhibitory effects on the development of
autoimmune diabetes (32, 33), together with T cell subsets.
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FIGURE 2 | Changes of gut permeability in NOD mice treated with IRT5. (A) The expression of tight junction proteins was evaluated by real-time RT-PCR using mRNA
from paraffin-embedded tissues and specific primers (n = 7 for NOD-PBS and 5 for NOD-IRT5). (B) The expression of ZO-1 protein was evaluated by
immunohistochemistry. (C) Gut permeability was determined by measuring serum FITC fluorescence 4 h after oral administration of FITC-dextran (n = 5 for NOD-PBS
and 5 for NOD-IRT5) (*p < 0.05; ns, not significant).
The proportions of CD3+, CD4+, or CD8+ T cells were not
significantly changed in PLNs, MLNs or SI-LP after IRT5
administration (Figure S3). Contrary to our expectation, the
proportion of CD4+FOXP3+ Treg cells was not significantly
changed in PLNs or MLNs after IRT5 administration for
12 weeks (Figure 3A). There was an increasing tendency of
CD4+FOXP3+ Treg cells in SI-LP of the treated mice; however,
the difference was statistically insignificant (Figure 3A). We
next studied the expression of CCR9 that can be expressed
in Treg cells and is required for T cell homing to the SI
(34, 35). We observed increased expression of CCR9 in CD4+
T cells from SI-LP (Figure 3B). The expression of CCR9
in CD4+ T cells was not significantly changed in PLNs or
MLNs after IRT5 administration, while there was an increasing
tendency of CCR9 in CD4+ T cells of PLNs (Figure 3B).
When we studied the changes of CCR9+ Treg cells, the
proportion of CCR9+CD4+FOXP3+ Treg cells was significantly
increased in PLNs and SI-LP but not in MLNs after IRT5
administration (Figure 3C), suggesting the role of gut-homing
Treg cells in the reduced incidence of autoimmune diabetes
by IRT5. To confirm the increases of CCR9+CD4+FOXP3+
Treg cells after IRT5 treatment, we calculate the numbers of
CCR9+CD4+FOXP3+ Treg cells in PLNs, MLNs or SI-LP.
Indeed, the numbers of CCR9+CD4+FOXP3+ Treg cells were
significantly increased in PLNs and SI-LP but not in MLNs
of NOD mice treated with IRT5 (Figure 3D), corroborating
the increases of CCR9+CD4+FOXP3+ Treg cells after IRT5
administration in PLNs and SI-LP.
Reduced Th1 Polarization by IRT5
We next studied whether IRT5 administration can change
the polarization of Th cells which affects the development of
autoimmune diabetes at the effector phase (36). We observed
that IRT5 administration significantly reduced the proportion
of CD4+IFN-γ+ Th1 cells in PLNs but not in MLNs or SI-LP
(Figure 4A). The proportion of CD4+IL-17A+ Th17 cells was
not significantly changed after IRT5 administration in PLNs,
MLNs or SI-LP (Figure 4A). We also studied skewing of CD8+ T
cells since CD8+ T cells are critical effector cells in autoimmune
diabetes and CD8+ T cells can be divided into multiple subsets
according to cytokine profile, similar to CD4+ T cells (37). The
proportions of CD8+IFN-γ+ Tc1 cells or CD8+IL17-A+ Tc17
cells were not significantly changed after IRT5 administration in
PLNs, MLNs or SI-LP (Figure 4B), suggesting that IRT5 inhibits
the development of autoimmune diabetes bymodulating skewing
of CD4+ T cells rather than that of CD8+ T cells.
DISCUSSION
We observed a significant decrease of diabetes incidence after
IRT5 administration for 36 weeks, which was associated with
reduced gut permeability and increased proportion of CCR9+
gut-tropic Treg cells. In this investigation, we started IRT5
administration at 4 weeks of age because previous studies
showed that inhibition of physiological β-cell apoptosis at day
14–42 with benzyloxylcarbonyl-V-A-D-O-methyl fluoromethyl
ketone (zVAD-fmk), a pan-caspase inhibitor, was able to
inhibit sensitization to diabetogenic T cells (38) and immune
intervention at 4 weeks of age could block the development of
diabetes in NOD mice (39–41). We continued IRT5 treatment
up to 40 weeks of age because diabetes developed even after
32–36 weeks of age in our NOD colonies (25). The reduction
of gut permeability by IRT5 is consistent with previous papers
showing decreased gut permeability by several Lactobacilli
in diverse conditions (42). The pathogenic role of increased
gut permeability due to dietary cause is widely accepted in
type 2 diabetes (43, 44). On the other hand, the mechanism
and immunological impact of altered gut permeability in
autoimmune diabetes are less clear. However, several papers
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FIGURE 3 | Treg cells in NOD mice treated with IRT5. (A) Cells from pancreatic lymph nodes (PLNs), mesenteric lymph nodes (MLNs), or lamina propria of the small
intestine (SI-LP) of NOD mice that were treated with IRT5 for 12 weeks were stained with anti-CD4 and -FOXP3 mAbs for flow cytometry gated on CD3 and CD4. The
percentages of CD4+FOXP3+ cells among CD3+CD4+ cells were compared (bottom). Representative scattergrams are shown (top). The numbers in the top right
quadrants represent the percentage of CD4+FOXP3+ Treg cells among CD3+CD4+ cells analyzed (n = 6 for NOD-PBS and 7 for NOD-IRT5 in PLNs; n = 6 for
NOD-PBS and 7 for NOD-IRT5 in MLNs; n = 9 for NOD-PBS and 9 for NOD-IRT5 in SI-LP). (B) Cells prepared as in (A) were stained with anti-CD4 and -CCR9 mAbs
for flow cytometry gated on CD3 and CD4. The percentages of CD4+CCR9+ cells among CD3+CD4+ cells were compared (bottom). Representative scattergrams
are shown (top). The numbers in the top right quadrants represent the percentage of CD4+CCR9+ Treg cells among CD3+CD4+ cells analyzed (n = 8 for NOD-PBS
and 8 for NOD-IRT5 in PLNs; n = 10 for NOD-PBS and 8 for NOD-IRT5 in MLNs; n = 7 for NOD-PBS and 7 for NOD-IRT5 in SI-LP). (C) Cells prepared as in (A) were
stained with anti-FOXP3 and -CCR9 mAbs for flow cytometry gated on CD4 and FOXP3. The percentages of CCR9+FOXP3+ cells among CD4+FOXP3+ cells were
compared (bottom). Representative scattergrams are shown (top). The numbers in the top right quadrants represent the percentage of CCR9+FOXP3+ Treg cells
among CD4+FOXP3+ cells analyzed (n = 7 for NOD-PBS and 12 for NOD-IRT5 in PLNs; n = 7 for NOD-PBS and 12 for NOD-IRT5 in MLNs; n = 9 for NOD-PBS and
10 for NOD-IRT5 in SI-LP). (D) The numbers of CCR9+CD4+FOXP3+ cells were calculated from the total numbers of lymphocytes, the percentages of CD3+CD4+
cells among total lymphocytes and that of CCR9+FOXP3+ cells among CD3+CD4+ cells (*p < 0.05; ns, not significant).
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FIGURE 4 | Th1/Th17 skewing in NOD mice treated with IRT5 for 12 weeks. (A) CD4+ Th cell skewing in PLNs, MSLs, or SI-LP was evaluated by flow cytometry. The
proportions of IFN-γ+ cells and IL-17+ cells among CD3+CD4+ T cells (right). Representative scattergrams are shown (left) (n = 5 for NOD-PBS and 5 for NOD-IRT5
in PLNs; n = 5 for NOD-PBS and 4 for NOD-IRT5 in MLNs; n = 5 for NOD-PBS and 5 for NOD-IRT5 in SI-LP). (B) CD8+ Tc cell skewing in PLNs, MSLs, or SI-LP was
evaluated by flow cytometry. The proportions of IFN-γ+ cells and IL-17+ cells among CD3+CD8+ T cells (right). Representative scattergrams are shown (left) (n = 5
for NOD-PBS and 5 for NOD-IRT5 in PLNs; n = 5 for NOD-PBS and 5 for NOD-IRT5 in MLNs; n = 5 for NOD-PBS and 5 for NOD-IRT5 in SI-LP) (*p < 0.05; ns, not
significant).
have shown increased gut permeability in T1D patients or
animal models of autoimmune diabetes (27–29). Morphological
changes of gut epithelium, such as reduced crypt length were
observed after administration of Akkermansia to NOD, which
was accompanied by delayed onset of diabetes (45). Alteration in
dietary components, gut bacteria, inflammation or other factors
may contribute to the increased gut permeability in autoimmune
diabetes, which is likely to affect immune tolerization or other
immune processes in gut epithelium, gut-associated lymphoid
tissues or PLNs, influencing autoimmune processes (46).
When we studied the immunological impact of IRT5
administration, we observed no significant change in the
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proportion of total Treg cells in PLNs, MLNs or SI-LP after in
vivo administration for 12 weeks. Such results are in contrast
to a significant induction of Treg cells in MLNs after IRT5
administration for 20 days (21), which could be due to differences
in disease models. Prolonged administration of IRT5 might
lead to the downregulation of immunological changes associated
with probiotics administration. Difference in other experimental
conditions, such as distinct mouse strain might be the cause of
discrepant results between studies.
Instead, we observed a significant increase in the percentage
of CCR9+ Treg cells, indicating that the proportion of
Treg cells with gut-homing capability was increased by IRT5
administration in vivo. Since CCR9, a gut-homing receptor, is
expressed in Treg cells and crucial in Treg cell homing to gut
tissue (35), an increased proportion of CCR9+ Treg cells after
IRT5 administration is likely to enhance Treg cell homing to
target tissues, such as the intestine or pancreas. In contrast, a
previous paper reported that a butyrate-producing probiotics
(Clostridium butyricum CB0313.1) increases total Treg cells in
PLNs with significant protection against autoimmune diabetes of
NODmice (7). Nonetheless, the induction of Treg cells with α4β7
gut-homing receptor was particularly prominent, suggesting
the importance of gut-homing Treg cells in probiotics-induced
protection against autoimmune diabetes (7). Despite significant
induction of Treg cells expressing CCR9, we observed no effect
of IRT5 administration on diabetogenic T cell priming in PLNs,
draining LNs for T cells reactive to islet β-cell antigens. Such
a failure to suppress diabetogenic T cell priming in PLNs by
Treg with gut-homing receptor is probably because Treg cells
act in target organs but not in draining LNs (32). CCR9+ T
cells interact with its ligand, CCL25, to enter target organs,
and CCR9+ Treg cells would exert their effect after homing
to target tissues through interaction with its ligand, which can
explain the absence of reduced diabetogenic T cell priming in
PLNs by IRT5. Consistent with the notion that Treg cells act
in target tissue, the decrease of the Treg cell:T effector cell
ratio was observed in pancreatic islets but not in PLNs of
NOD mice (47). Increased FOXP3+ cell number has also been
found in pancreatic islets after the treatment of NOD mice with
Akkermansia, which was accompanied by delayed development
of diabetes (45). Significant increases of CCR9+ Treg cells in SI-
LP observed in this study also support the role of CCR9 on gut
homing and potential effect of CCR9+ Treg cells in target tissues.
No significant changes of total Treg cells in PLNs might also
contribute to the absence of IRT5 effect on diabetogenic T cell
priming in PLNs.
Th1 polarization is an important step in the pathogenesis
of autoimmune diabetes in NOD mice (36). Furthermore, IRT5
can downregulate Th1/Th17 polarization through generation of
regulatory DCs and subsequent induction of Treg cells (20). We
observed reduced skewing to Th1 producing IFN-γ in PLNs
by IRT5 administration, and similar changes were observed in
MLNs or SI-LP but without statistical significance. Since Th1
cells producing IFN-γ are main effector cells in autoimmune
diabetes (36, 48), reduced Th1 skewing by IRT5 is likely to
contribute to the reduced incidence of autoimmune diabetes
by IRT5. Significant changes of the proportion of Th1 cells in
PLNs without alteration of diabetogenic T cell priming by IRT5
treatment could be due to differences in signal transduction and
proliferative response between naïve cells and primed T cells
(49, 50). Recirculation of effector T cells back and forth between
target tissues and draining lymph nodes (51, 52) might also
contribute to the reduced Th1 cells in PLNs because CCR9+
Treg cells are likely to act on effector T cells in pancreatic
islets after homing to target tissues and such effector T cells
may move back to PLNs. In contrast to the skewing to Th1,
skewing to Th17 producing IL-17A was not changed by IRT5
administration, while the role of Th17 cells in autoimmune
diabetes begins to be recognized (53). Although the effect of
IRT5 reducing the incidence of autoimmune diabetes of NOD
mice is most likely due to induction of gut-homing Treg
cells and reduced Th1 polarization, other mechanisms have
been suggested, such as restoration of antigen-specific tolerance
or induction of IL-10 when genetically-modified Lactococcus
lactis or a probiotic combination consisting of Bifidobacteria,
Lactobacilli, and Streptococcus salivarius subsp. Thermophiles was
employed (6, 54).
In conclusion, we observed significantly reduced incidence
of autoimmune diabetes in NOD mice by administration of
a probiotic combination comprising 5 bacteria, which can be
explained by reduced gut permeability, increased generation of
gut-homing Treg cells and reduced Th1 polarization. However,
autoimmune diabetes of NOD mice was not completely
abrogated by our probiotic combination, which could be a
drawback in the clinical application of IRT5 to the prevention or
treatment of autoimmune diabetes. Further optimization of IRT5
by combining with other bacteria or their products comprising
active components may lead to the discovery of effective
therapeutic or preventive compounds that can be safely used for
human trial or clinical purposes. Because we recently identified
cell surface β-glucan/galactan polysaccharide of Bifidobacterium
bifidum as an active molecule inducing Treg cells (55), IRT5
or their active components could be candidates of therapeutic
agents for human immune disorders in future studies.
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